We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
ClinicalTrials.gov Menu

AtriCure Exclusion of the LAA in Patients Undergoing Concomitant Cardiac Surgery (EXCLUDE)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00779857
Recruitment Status : Completed
First Posted : October 24, 2008
Results First Posted : June 4, 2013
Last Update Posted : June 4, 2013
Information provided by (Responsible Party):
AtriCure, Inc.

Brief Summary:
Prospective, non-randomized trial to evaluate the safety and efficacy of the LAA Exclusion Device (Clip) for the exclusion of the LAA via epicardial tissue approximation.

Condition or disease Intervention/treatment Phase
Left Atrial Appendage Exclusion Device: AtriCure LAA Exclusion System Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 70 participants
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Exclusion of the Left Atrial Appendage With the AtriClip LAA Exclusion Device in Patients Undergoing Concomitant Cardiac Surgery
Study Start Date : September 2008
Actual Primary Completion Date : October 2009
Actual Study Completion Date : October 2011

Arm Intervention/treatment
Experimental: AtriCure LAA Exclusion System
AtriCure LAA Exclusion System
Device: AtriCure LAA Exclusion System
Exclusion of the left atrial appendage using the AtriCure LAA Exclusion System

Primary Outcome Measures :
  1. Rate of Device Related Serious Adverse Events [ Time Frame: Discharge/30 days Post Procedure ]
    The primary safety endpoint is the rate of device related serious adverse events within 30 days post-procedure or hospital discharge, whichever is later, compared with the rates for serious adverse events for LAA exclusion reported in the peer review literature. The safety endpoint was determined based on an independent review of all reported adverse events by an independent cardiac surgeon that was not an investigator in the study.

  2. Percent of Patients With Complete Occlusion of the Left Atrial Appendage. [ Time Frame: 3 Months Post Procedure ]
    The primary efficacy endpoint is defined as the complete exclusion of the LAA defined by lack of fluid communication between the LA and LAA at both intra-operative (TEE) and 3 month (CT) evaluations and intra-operative verification of completeness of LAA exclusion.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Subject is greater than or equal to 18 years of age.
  2. Subject has any one of the following risk factors and is thought to benefit from LAA occlusion:

    • CHADS score > 2
    • Age > 75 years
    • Hypertension and age > 65 years
    • Previous stroke
    • History of atrial fibrillation (any classification)
  3. Subject is scheduled to undergo elective non-endoscopic cardiac surgical procedure(s) including cardiac surgery for one or more of the following: Mitral valve repair or replacement, Aortic valve repair or placement, Tricuspid valve repair or replacement, Coronary artery bypass procedures, concomitant surgical (ablation or cut-and-sew) Maze procedure, patent foramen ovale (PFO), atrial septal defect (ASD) repair with the device deployed while on or prepared for cardio-pulmonary bypass support.
  4. Subject is willing and able to provide written informed consent.
  5. Subject has a life expectancy of at least 1 year.
  6. Subject is willing and able to return for scheduled follow-up visits.

Exclusion Criteria:

  1. Previous cardiac surgery
  2. Thrombus in the LAA/LA which cannot be evacuated prior to placement of the Clip.
  3. Patients requiring surgery other than CABG and/or cardiac valve and/or surgical maze procedure and/or PFO closure and/or ASD repair.
  4. NYHA Class IV heart failure symptoms
  5. Need for emergent cardiac surgery (i.e. cardiogenic shock)
  6. Creatinine >200 µmol/L
  7. LAA is not appropriate for exclusion based on intraoperative evaluations
  8. Current diagnosis of active systemic infection
  9. Renal failure requiring dialysis or hepatic failure
  10. A known drug and/or alcohol addiction
  11. Mental impairment or other conditions which may not allow the subject to understand the nature, significance and scope of the study
  12. Pregnancy or desire to get pregnant within 12-months of the study treatment
  13. Preoperative need for an intra-aortic balloon pump or intravenous inotropes
  14. Patients who have been treated with thoracic radiation
  15. Patients in current chemotherapy
  16. Patients on long term treatment with steroids not including intermittent use of inhaled steroids for respiratory diseases.
  17. Patients with known connective tissue disorders

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00779857

Layout table for location information
United States, Georgia
Macon Medical Center
Macon, Georgia, United States, 31201
United States, Indiana
St. Francis Heart Hospital
Indianapolis, Indiana, United States, 45237
United States, Michigan
Spectrum Health
Grand Rapids, Michigan, United States, 49506
United States, Missouri
Washington University School of Medicine
St. Louis, Missouri, United States, 63110
United States, Ohio
Mount Carmel East Hospital
Columbus, Ohio, United States, 43213
United States, Texas
Baylor Heart Hospital
Plano, Texas, United States, 75093
United States, Virginia
University of Virginia
Charlottesville, Virginia, United States, 22908
Sponsors and Collaborators
AtriCure, Inc.
Layout table for investigator information
Principal Investigator: Michael Mack, MD Baylor Heart Hospital
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Layout table for additonal information
Responsible Party: AtriCure, Inc.
ClinicalTrials.gov Identifier: NCT00779857    
Other Study ID Numbers: CP2008-2
First Posted: October 24, 2008    Key Record Dates
Results First Posted: June 4, 2013
Last Update Posted: June 4, 2013
Last Verified: May 2013
Keywords provided by AtriCure, Inc.:
left atrial appendage
atrial fibrillation